GJA1 and glioblastoma: In line with the fact that Cx43 levels are much higher than other connexins in GBM (Fig. 1) and the finding that Cx43 controls chemoresistance (Figs. 2–5), Cx43 is therefore the prime therapeutic target for GBM among all connexins.